This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Delving into the recent data from the phase 3 GRAVITI and GALAXI clinical trials of Tremfya in patients with Crohn's disease
Ticker(s): JNJ, LLYWho's the expert?
Institution: The lowa Clinic
- General gastroenterologist working in the Midwest at a large multi clinic practice that is independently owned.
- Sees a variety of Gl conditions including significant inflammatory bowel disease, significant liver disease, IBS, and others.
- Participated in market research surveys and interviews for many years
Interview Goalto discuss the current treatment landscape and the potential of TREMFYA (guselkumab), an IL-23 inhibitor developed by Eli Lilly and Johnson & Johnson for the treatment of Crohn's disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
